A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy
Clinical trial NCT06456463 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06456463
- Sponsor
- Stemline Therapeutics, Inc.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-01-14
- Primary completion
- 2028-02-09
- Enrollment
- 85
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.